Genetic variants in DNA repair enzymes contribute to the susceptibility to cutaneous melanoma; consequently, we analyzed whether common nonsynonymous single-nucleotide polymorphisms in DNA repair enzyme genes might also influence the course of disease. To this end, we determined eight polymorphisms of seven different DNA repair enzymes in 742 patients with cutaneous melanoma, and correlated these with overall survival. Univariate Cox proportional hazards model analyses revealed that ERCC5 (XPG) 1104 His/His was significantly associated with impaired survival. Indeed, the univariate hazard ratio (HR) was 2.8 times higher for patients with ERCC5 1104 His/His (Po0.001) compared with ERCC5 1104 Asp/Asp. Accordingly, the 5-year survival rate was 55% (95% confidence interval 43-71) for patients with ERCC5 1104 His/His, whereas 82% (95% confidence interval 78-86) of patients with ERCC5 1104 Asp/Asp were still alive at this time. Importantly, adjusted Cox regression analysis not only confirmed ERCC5 1104 His/His as an independent prognostic factor (multivariate HR ¼ 4.5; Po0.001), but also revealed the significant impact of ERCC2 (XPD) 751 Gln/Gln on prognosis, with a 2.2-fold increased HR compared with ERCC2 751 Lys/Lys (P ¼ 0.009). Thus, ERCC5 codon 1104 and ERCC2 codon 751 polymorphisms are independent prognostic factors in patients with cutaneous melanoma.
INTRODUCTION
Malignant melanoma is an aggressive cancer with a high mortality rate once metastasized. One of the major risk factors for melanoma is sun exposure (Halpern and Altman, 1999) . Notably, UV radiation causes various kinds of DNA damage. UVB, i.e., 280-315 nm, provokes DNA damage by cyclobutane pyrimidine dimers and pyrimidine photoproducts, whereas wavelengths of 315-400 nm, i.e., UVA, cause single-strand breaks, DNA-protein crosslinking, and generation of free oxidative radicals (Pfeifer et al., 2005) . As unrepaired DNA damage can either result in apoptosis or DNA aberrations leading to unregulated cell growth and cancer, cells are endued with various DNA repair pathways that are activated upon DNA damage.
In order to maintain the integrity of the genome, at least four different pathways of DNA repair operate on specific types of damaged DNA. For example, base excision repair (BER) corrects small DNA lesions such as oxidized or reduced bases, as well as fragmented or nonbulky adducts. The nucleotide excision repair (NER) pathway repairs bulky lesions such as pyrimidine dimers, larger chemical adducts, or DNA crosslinks. In addition, at least two pathways to repair double-strand breaks exist, i.e., the homologous recombination pathway and the nonhomologous end-joining repair pathway (reviewed in Goode et al., 2002) .
As maintenance of DNA integrity is important to prevent carcinogenesis, genes encoding DNA repair molecules are prime candidates for cancer-susceptibility genes (Bartsch et al., 2007) . Indeed, several single-nucleotide polymorphisms (SNPs) in these genes have been implicated in increased cancer susceptibility (Kiyohara and Yoshimasu, 2007; Naccarati et al., 2007) : e.g., ERCC2 (XPD) 751 Gln and XRCC3 241 Met are both associated with an increased risk to develop cutaneous melanoma (Winsey et al., 2000; Li et al., 2006a) . However, genetic variation in DNA repair enzymes might also affect the clinical course of cancer by, e.g., affecting genetic stability (Umar and Kunkel, 1996; Kloor et al., 2010) . Indeed, it has been recently reported that primary melanomas overexpressing DNA repair genes are characterized by an impaired prognosis (Kauffmann et al., 2008) . The authors hypothesized that tumor cells in the process of metastasis try to replicate in a fast and error-free mode to maintain those genetic aberrations associated with a growth advantage. To further extent this notion, we scrutinized the prognostic impact of polymorphic variation in DNA repair genes on the course of melanoma by analyzing eight SNPs in a cohort of 742 melanoma patients. All of the addressed SNPs are nonsynonymous. The included SNPs were xeroderma pigmentosum complementation group C (XPC) p.Ala499Val and XPC p.Lys939Gln, excision repair cross-complementing rodent repair deficiency, complementation group 2 (ERCC2; alias XPD) p.Lys751Gln and ERCC5 (XPG) p.Asp1104His all involved in NER, APEX1 (APEX nuclease (multifunctional DNA repair enzyme) 1) p.Asp148Glu and X-ray repair complementing defective repair in Chinese hamster cells 1 (XRCC1) p.Arg399Gln both participating in BER and XRCC3 p.Thr241Met and Nijmegen break syndrome mutated gene (NBN; NBS1) p.Glu185Gln, i.e., molecules of the homologous recombination repair pathway. This analysis revealed that ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln have a significant and independent impact on the clinical course of melanoma.
RESULTS

Patient characteristics
Of the 742 patients, 328 were female (44. 2%) and 414 male (55.8%). Superficial spreading melanoma (346 patients) and nodular melanoma (182 patients) were the most common histological diagnoses. The median age at diagnosis of the patient cohort was 54.8 years and the median follow-up time was 74.2 months. A total of 226 patients died during the follow-up period. The detailed patient and tumor characteristics are presented in Table 1 .
Genotyping frequencies of polymorphisms and survival
The allelic and genotypic frequencies of SNPs are given in Table 2 . Notably, from the majority of samples the genotype could be determined; only 4 to 12.9%, with an average of B7.6%, of samples did not give a distinct result. The observed genotype frequencies were in the range of the frequencies reported on the respective SNP database websites of the National Center for Biotechnology Information. From the analyzed SNPs only XPC p.Lys939Gln and XPC p.Ala499Val were statistically significant in linkage disequilibrium after Bonferroni-Holmes adjustment (Po0.001; D' ¼ 0.906; r 2 ¼ 0.19). This linkage disequilibrium for the two XPC SNPs has been published previously (Huang et al., 2006) .
The effect of each polymorphism on overall survival was estimated by the Kaplan-Meier method, revealing that ERCC5 p.Asp1104His has a significant impact on overall survival (Po0.001; log-rank test): ERCC5 1104 His/His was associated with a highly impaired prognosis compared with ERCC5 1104 His/Asp or Asp/Asp (Figure 1 ). This observation was confirmed by the 5-year survival rate (Table 3) : 153 patients died during the first 5 years after diagnosis, and 469 patients had a follow-up time of 460 months. Validated prognostic factors such as age, gender, tumor classification, and clinical stage at diagnosis influenced the 5-year survival significantly, thereby demonstrating that our cohort is representative for the general melanoma population (Balch et al., 2001b) . Notably, from the analyzed DNA repair gene SNPs, only ERCC5 1104 polymorphisms significantly influenced the 5-year survival rate. Indeed, the survival impact was obvious in both the whole patient population and the gender subgroups. In this regard, the 5-year survival rate was 82% (95% confidence interval 78-86) for ERCC5 1104 Asp/Asp versus 56% (95% confidence interval 43-71) for His/ His (Po0.001; log-rank test).
Hazard ratio (HR) for DNA repair polymorphisms Next, we calculated the HRs for DNA repair SNPs by univariate and multivariate Cox regression analyses. The univariate analyses confirmed that gender, age, tumor classification, and stage at diagnosis as well as ERCC5 p.Asp1104His polymorphisms influenced the risk to die from melanoma ( Figure 2 ). The HR for ERCC5 1104 His/His was 2.8 times higher than for ERCC5 1104 Asp/Asp (Po0.001). Additionally, the ERCC2 p.Lys751Gln polymorphism, for which we observed a trend in the 5-year survival analysis, significantly influenced prognosis: patients with ERCC2 751 Gln/Gln had a 1.7 times increased risk to die compared with ERCC2 751 Lys/Lys patients (P ¼ 0.035). To test whether ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln are independent prognostic factors, we performed multivariate Cox regression analysis. For this analysis, we adjusted each SNP to each other as well as to the known prognostic parameters gender, age, and stage at diagnosis. In order to decrease the number of patient subgroups, stage IIB and IIC as well as stage IIIB and IIIC patients were grouped. These analyses confirmed ERCC5 1104 His/His (HR ¼ 4.5; Po0.001) and ERCC2 751 Lys/Lys (HR ¼ 2.2; P ¼ 0.009) as independent prognostic factors for overall survival of cutaneous melanoma patients ( Figure 3 ). All results of the multivariate analyses were confirmed by bootstrapping, i.e., analysis of randomly selected patient cohorts. DISCUSSION DNA repair is essential to ensure integrity and stability of the genome. Genetic instability is responsible for the cellular changes that confer progressive transformation on cancerous cells; thus, defects in DNA repair can be expected to promote cancer. Indeed, patients with XP, an autosomal recessive disease associated with defective NER, have a 1,000-fold higher susceptibility for skin cancer (Kraemer et al., 2007) . The ability to repair DNA damages, however, also varies to a considerable extent within the normal human population. These variations could be a consequence of common polymorphic amino-acid substitutions in DNA repair genes (Mohrenweiser et al., 2003) . Consequently, many studies have been performed to reveal possible associations between SNPs in DNA repair genes and susceptibility to cancer (Berwick and Vineis, 2000; Goode et al., 2002) . Most studies, however, do not address whether such variations in DNA repair impact on the clinical course of cancer. Several lines of evidence suggest that this may be the case: for melanoma, genomic instability is not only increased in primary tumors when compared with nevi, but also in metastases when compared with primary tumors (Chin et al., 2006) ; similarly, hypoxia, which is associated with an aggressive phenotype of cancer, mediates among other changes genetic instability (Bristow and Hill, 2008) . Thus, we scrutinized whether common nonsynonomous SNPs in DNA repair genes are related to the progression of melanoma in a cohort of 4700 melanoma patients for whom detailed information and a close follow-up was available. The majority of the analyzed SNPs were selected as they are among the most studied DNA repair gene SNPs for melanoma susceptibility (Li et al., 2006a, b; Mocellin et al., 2009) . In addition, the NBN SNP was included as germline mutations have been described for melanoma (Steffen et al., 2004) . Our study revealed that ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln are independent prognostic factors for the clinical course of melanoma. Interestingly, although ERCC2 SNP has been described as melanoma susceptibility SNP in one study (Li et al., 2006a) , a large study of almost 1,200 melanoma patients as well as a review of the literature could not reveal an impact of these two SNPs on the susceptibility for melanoma (Figl et al., 2010) .
The number of studies addressing the association between SNPs in DNA repair genes and the course of neoplastic diseases is surprisingly low, particularly if compared with those addressing cancer susceptibility. This is probably because of the fact that the diagnosis of cancer itself is more widely available than the detailed medical history. Consequently, studies addressing SNPs as prognostic factors are largely characterized by a low patient number. For example, in a recent study scrutinizing three DNA repair SNPs, i.e., XRCC1 p.Arg399Gln, ERCC2 p.Lys751Gln, and ERCC1 p.Thr118Cys, and their association with survival in stage IV melanoma patients receiving biochemotherapy, only 90 patients were included (Liu et al., 2005) . This analysis, however, revealed that the ERCC1 polymorphism was weakly associated with overall survival, and the Gln allele of the ERCC2 polymorphism was unfavorable without reaching significance. In contrast to our study, Liu et al. (2005) searched for a predictive marker, whereas we addressed prognostic markers for melanoma. Moreover, the study of Liu et al. (2005) is likely to be underpowered to reach a significant result for ERCC2. Interestingly, ERCC2 p.Lys751Gln was suggested to be a prognostic factor for melanoma progression, as in 244 Swedish patients the Lys/ Gln phenotype was more frequent in patients with advanced melanoma (Kertat et al., 2008) . In a previous study of 400 melanoma patients, Figl et al. (2009) reported XRCC1 p.Arg399Gln to be associated with prognosis: patients with XRCC1 Gln/Gln demonstrated a median overall survival of 24.4 years compared with 11.5 years for the two other genotypes. In the same study, however, this association was not detectable in an independent Spanish patient cohort selected by the same criteria, i.e., only patients first diagnosed at stage I or II. The authors concluded that this may have been because of the fact that only a few deaths were recorded for this cohort. In our study, although the independent patient cohort reflects the whole variety of tumor stages at diagnosis translating into a worse survival rate, we were not able to confirm the previous results. This observation demonstrates the importance of conducting multiple studies on potential biomarkers. Alternatively, supportive evidence might come from more frequent cancer entities analyzing the impact of variations in DNA repair on the course of disease. For example, in a large study of lung cancer patients, the authors detected 15 nonsynonomous SNPs associated with prognosis (Matakidou et al., 2007) ; these primarily mapped to the NER and BER repair pathways, and ERCC5 p.Asp1104His was among the most significant ones. Thus, ERCC5 p.Asp1104His seems to be associated with prognosis in different cancer entities. Notably, in contrast to a previous report by Di Lucca et al. (2010) , we did not find an association between ERCC5 p.Asp1104His-nor any other of our analyzed-genotypes and Breslow thickness.
Indeed, in multivariate analysis with tumor class instead of tumor stage, we obtained the same results (data not shown).
To date, all SNPs associated with prognosis belong to the NER and BER pathways. This notion is further corroborated by the observation that in early small cell lung cancer patients a higher expression of DNA synthesis and repair enzymes RRM1 and ERCC1 in the tumors was associated with a better overall survival (Zheng et al., 2007) . However, the picture is getting more complex as it has recently been demonstrated that primary melanomas with poor prognosis overexpress DNA repair genes (Kauffmann et al., 2008) . Indeed, the majority of these overexpressed genes code for proteins involved in rescuing stalled DNA replication forks, DNA double-strand break/interstrand crosslink repair, and telomere maintenance. Similar results were obtained in a larger study, in which overexpression of DNA repair genes and genes involved in cell cycle progression was observed in samples of relapsing compared with nonrelapsing patients (Jewell et al., 2010) . Thus, it seems that a defective or impaired DNA repair system can contribute to the initiation of tumors, whereas in the tumor stage patients whose tumors express larger amounts of DNA repair enzymes present with a faster relapse. This overexpression of DNA repair genes might allow the fast-growing cancer cells to replicate more correctly and thereby to prevent severe, i.e., deleterious, DNA damage. Somehow surprisingly, however, metastatic sites often demonstrate higher levels of genetic instability (Balazs et al., 2001) , and in mice the metastatic potential of tumor cells is associated with increasing genetic instability (Cifone and Fidler, 1981) . As it is known that E2F integrates cell cycle progression with DNA repair (Ren et al., 2002) , overexpression of DNA repair genes can at least in part be ascribed to increased proliferation.
The precise mechanism of how the ERCC5 and ERCC2 SNPs influence overall survival in cutaneous melanoma patients remains elusive; as always for disease-associated SNPs, the cancer phenotype could be altered in two ways: either directly by altering the DNA repair capacity of the tumor cell or indirectly by being in linkage disequilibrium with other disease-modulating alleles. ERCC5 and ERCC2 are core proteins of the NER pathway and therefore play crucial roles in the correction of cyclobutane pyrimidine dimers, 6-4 photoproducts, and bulky adducts induced by chemical agents (Costa et al., 2003) . The potential of amino-acid substitutions encoded by SNPs to impact protein structure and activity can be predicted by two different algorithms: i.e., SIFT (Sorting Intolerant from Tolerant) and PolyPhen (Polymorphism Phenotyping). These algorithms are based on sequence conservation over evolutionary time, the physical and chemical properties of the exchanged residues, and/or protein structural domain information. Several benchmarking studies have demonstrated that these algorithms predict protein function very correctly (reviewed in Xi et al., 2004) . Both the SIFT and the PolyPhen algorithms estimate the His substitution of Asp at codon 1104 of ERCC5 as intolerant or possible damaging, whereas the Lys substitution by Gln at codon 751 of ERCC2 was predicted by both programs as benign. However, functional analysis of the respective amino-acid substitutions is still the gold standard. To this end, we recently demonstrated for XPG Asp1104His that TT ¼ T dimer repair was nonsignificantly lower in heterozygotes compared with the homozygous wild type (Kumar et al., 2003) ; furthermore, we demonstrated an association between this SNP and the level of single-strand breaks (Vodicka et al., 2004) . In contrast, for ERCC2 751 variant proteins no difference in NER activity was detectable (Laine et al., 2007) . This observation, on one hand, confirms the results of the prediction algorithms and, on the other hand, argues that there is no causal relationship between ERCC2 p.Lys751Gln polymorphism and reduced DNA repair (Clarkson and Wood, 2005) . However, Wolfe et al. (2007) recently demonstrated that the minor allele of ERCC2 751 is associated with decreased constitutive ERCC2 mRNA levels caused by an altered mRNA secondary structure. This reduced expression of the mRNA may explain the increased number of DNA adducts in individuals carrying Gln alleles suggesting lower DNA repair capacity in these individuals (reviewed in Benhamou and Sarasin, 2005) . It should be further noted that besides their function in NER, ERCC2 is involved in transcriptional regulation (Schaeffer et al., 1993) , and ERCC5 acts as a cofactor for a DNA glycosylase; an enzyme that removes oxidized pyrimidines from DNA. Moreover, ERCC5 has also been involved in both transcription-coupled repair and RNA transcription itself (Clarkson, 2003) . The SNPs in these genes may therefore affect not only NER, but also any of these functions. In conclusion, in this study we identified ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln as independent prognostic factors for the clinical course of melanoma. Whether these SNPs impact the prognosis of melanoma directly via alteration of DNA repair efficacy or by other, possibly indirect, mechanisms has to be addressed by future studies. In any case, identification of prognostic factors will help to individualize and optimize medical care of patients; i.e., high-risk patients should receive a closer follow-up and should be considered for adjuvant therapy.
PATIENTS AND METHODS
Patients and sera
Serum samples were selected from frozen serum banks hosted by Skin Cancer Unit, Mannheim and the Department of Dermatology, Wuerzburg. Serum samples to be included in the analysis were chosen randomly but selected to meet the following criteria: (1) histological confirmation of primary cutaneous melanoma, (2) patient of Caucasian origin, and (3) availability of extended information of the medical history, primary tumor characteristics, as well as patient follow-up. The only exclusion criteria were sera from patients with secondary malignancies or in situ melanoma. The detailed patient characteristics are given in Table 1 . All serum samples were obtained and processed following a standardized protocol. Briefly, blood was drawn into gel-coated serum tubes (Sarstedt, Nuembrecht, Germany) and allowed to clot at room temperature for 30-60 minutes. After centrifugation, the serum phase was harvested and subsequently frozen without any additives at À20 1C. All measures were performed with the approval of the institutional review board after patients' informed consent and in adherence to the Declaration of Helsinki Principles.
Genotyping DNA was extracted from 200 ml serum of each cryopreserved sample with the QIAamp DNA mini kit (Qiagen, Hilden, Germany) as described by the manufacturer and genotyped for eight different Figure 2 . Univariate hazard ratios (HRs) for overall survival. All factors analyzed are depicted. Dots represent the HRs, lines the 95% confidence intervals (CIs). In cases where the HRs and/or the CIs are beyond the depicted range, the values are given. A polymorphism is relevant when the respective CI does not cross the value 1.
1 Patient numbers for each analysis are given in Table 1 and Table 2 , respectively.
www.jidonline.org 1287 D Schrama et al.
ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln in Melanoma SNPs in DNA repair genes including the NER genes XPC (A4C; p.Lys939Gln; rs2228001), XPC (C4T; p.Ala499Val; rs2228000), ERCC2 (A4C; p.Lys751Gln; rs13181), and ERCC5 (G4C; p.Asp1104His; rs17655); the BER genes APEX1 (T4G; p.Asp148Glu; rs1130409) and XRCC1 (G4A; p.Arg399Gln; rs25487); and the double-strand break repair genes XRCC3 (C4T; p.Thr241Met; rs861539) and NBN (G4C; p.Glu185Gln; rs1805794). All these polymorphisms included in the study were nonsynonymous and have minor allele frequencies 40.2 (Table 2) . Genotyping was performed by the 5 0 nuclease allelic discrimination assay in TaqMan technology (Applied Biosystems, Foster City, CA). TaqMan primers and probes were purchased from Applied Biosystems as assays on demand (C_16018061_10 for rs2228001 and C_622564_10 for rs861539) or by own design for all others (Supplementary Table S1 online). PCR was performed in 5 ml volume reaction using 5 ng DNA as template, master mix (Applied Biosystems), and 0.5 Â probe/ primer mix. The initial temperature conditions for PCR were set at 50 1C for 2 minutes and 95 1C for 10 minutes followed by 40-45 cycles at 92 1C for 15 seconds and 60 1C for 1 minute. Genotyping on amplified PCR products was scored by differences in VIC and 5-carboxyfluorescein, succinimidyl ester (FAM) fluorescent level in plate read operation on ABI PRISM 7900HT sequence detection system (Applied Biosystems) using SDS 1.2 software (Applied Biosystems).
Genotyping results from allelic discrimination assays were randomly verified by DNA sequencing. The sequencing reactions were performed using BigDyeR Terminator Cycle Sequencing Kit (Applied Biosystems) in a 10 ml volume containing PCR product pre-treated with ExoSapIT (USB Corporation, Cleveland, OH), 5 Â Sequencing buffer (Applied Biosystems), and a sequencing primer. The temperature conditions set for sequencing reactions were 96 1C for 2 minutes followed by 27 cycles at 96 1C for 30 seconds, 54 1C for 10 seconds, and 60 1C for 4 minutes. Sequencing reaction products were precipitated with 2-propanol, washed with 75% ethanol, resuspended in 25 ml water, and loaded onto ABI prism 3100 Genetic analyzer (Applied Biosystems). Primary sequencing data were analyzed using the accompanied sequence analysis program (Applied Biosystems).
Statistical methods
Data were analyzed by the statistic software R (version 2.8) available at http://www.r-project.org using the libraries ''survival'' and ''genetics.'' Age was categorized into three groups (age p45, 46-60, and 460 years). Each genotype-variable was dichotomized into three individual variables. For univariate analyses, the Kaplan-Meier method was used to compare survival times between groups. Differences in 5-year survival rates and survival times were assessed by the log-rank test. In addition, for univariate as well as multivariate analyses, Cox's proportional hazards regression model was applied with dichotomized variables. As the majority of the melanoma-associated events happen within the first 5 years after diagnosis, close follow-up according to the German guidelines is only recommended for this time period (Garbe et al., 2007) . Consequently, we censored our patient cohort after this period. To scrutinize and validate relevant variables, multiple analyses including backward and forward stepwise Cox regressions were performed. Linkage disequilibrium was calculated with the function linkage disequilibrium of the library ''genetics.'' All presented multivariate regression models were evaluated by bootstrap methods according to the recommendations of Altman and Andersen (1989) .
